Synonyms: compound I-10 [WO2020233716A1] [1]
Compound class:
Synthetic organic
Comment: This compound is a small molecule inhibitor of mitogen-activated protein kinase-interacting protein kinases (MNKs) 1 and 2 [2]. It was designed to treat malignancies with MNK/eukaryotic translation initiation factor 4E (eIF4E) axis defects; the MNKs being essential for eIF4E phosphorylation and regulation.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Chen C, Zhang H, Yuan X, Zhou J, Hong J. (2020)
Imidazopyridazine mnk1/mnk2 kinase inhibitors, preparation method therefor and use thereof. Patent number: WO2020233716A1. Assignee: Shanghai Daoen Biotechnology Co., Ltd., Shanghai Medici Biopharmaceutical Co., Ltd.. Priority date: 22/05/2020. Publication date: 26/11/2020. |
2. Yuan X, Guan D, Chen C, Guo S, Wu H, Bu H, Yang CY, Wang M, Zhou J, Zhang H. (2024)
Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma. J Med Chem, 67 (7): 5437-5457. [PMID:38564512] |